Active material: Imidazoliletanamid pentandiovoy acid (vitaglutam)
When ATH: J05AX
CCF: Viricide
ICD-10 codes (testimony): J10
When CSF: 09.01.05.02
Manufacturer: Valenti PHARMACEUTICS JSC (Russia)
Capsules of blue color, size №2; содержимое капсул – гранулы и порошок белого или белого с кремоватым оттенком цвета.
| 1 caps. | |
| imidazoliletanamid pentandiovoy acid (vitaglutam) | 30 mg |
Excipients: lactose, potato starch, colloidal silicon dioxide (aэrosyl), magnesium stearate.
Ingredients of the capsule shell: Titanium dioxide, dye Brilliant Black (Black Diamond), patented blue dye (Patent blue), carmine dye (poncho 4R), azoruʙin, gelatin.
7 PC. – упаковки ячейковые контурные (1) – пачки.
Capsules of red color, size №1; содержимое капсул – гранулы и порошок белого или белого с кремоватым оттенком цвета.
| 1 caps. | |
| imidazoliletanamid pentandiovoy acid (vitaglutam) | 90 mg |
Excipients: lactose, potato starch, colloidal silicon dioxide (aэrosyl), magnesium stearate.
Ingredients of the capsule shell: Titanium dioxide, quinoline yellow, carmine dye (poncho 4R), azoruʙin, gelatin.
7 PC. – упаковки ячейковые контурные (1) – пачки.
Viricide. It is active against influenza A and influenza B, adenoviral infection.
In experiments in vitro and in vivo to effectively inhibit reproduction and cytopathic effect of the virus of influenza A and influenza B, Adenovirus. The antiviral mechanism of action caused by the suppression of viral reproduction at step Nuclear phase, delayed migration of newly synthesized NP virus from the cytoplasm to the nucleus.
It has a modulating effect on the functional activity of interferon: It causes an increase in the content of interferon in the blood to physiological norms, It stimulates and normalizes the reduced α-interferonprodutsiruyuschuyu ability of white blood cells, It stimulates γ-interferonprodutsiruyuschuyu ability of white blood cells.
It causes the generation of cytotoxic lymphocytes, and increases the content of NK T-lymphocytes, possessing high killer activity against virus-transformed cells and a pronounced antiviral activity.
The anti-inflammatory effect is due to inhibition of the production of key proinflammatory cytokines (FNOα, ИЛ-1b и ИЛ-6), reduction of myeloperoxidase activity.
The therapeutic efficacy of the flu is manifested in shortening the period of fever, reduction intoxication (headache, weakness, dizziness), catarrhal symptoms, reducing the number of complications and duration of the disease.
Absorption and distribution
When used in the recommended doses definition plasma drug available methods it is not possible.
In experimental studies using radioactive label was established, that the drug rapidly enters the blood from the gastrointestinal tract and is distributed evenly over the internal organs.
Cmax in blood, blood plasma and most organs are achieved through 30 minutes after administration. AUC values kidney, liver and lungs slightly higher than AUC blood (43.77 g × h / g). AUC values spleen, adrenal, lymph nodes and thymus enlarge blood AUC. Среднее время удержания препарата в крови – 37.2 no.
At 5-day course of oral administration 1 time / day is its accumulation in internal organs and tissues. Moreover the qualitative characteristics of pharmacokinetic curves after each injection were identical: a rapid increase of drug concentration following each administration and then slowly fall to 24 sometimes.
Metabolism and excretion
Do not metabolized in the body and is excreted unchanged in.
The basic process excretion occurs within 24 no. During this time the output 80% dose. For the first 5 h output 34.8%, в последующие часы – 45.2%. Of those displayed in the feces 77%, с мочой – 23%.
- Treatment of Influenza (при необходимости – в сочетании с приемом симптоматических средств).
The drug is taken orally by 90 mg 1 times / day for 5 days, regardless of the meal.
The drug should be started with the appearance of the first symptoms of the disease, not later 36 h From the onset of illness.
Rarely: allergic reactions.
- Pregnancy;
- Childhood and adolescence up 18 years;
- Hypersensitivity to the drug.
Use of the drug during pregnancy has not been studied.
If necessary, use during lactation should decide the issue of termination of breastfeeding.
Toxicological studies indicate low toxicity and high safety profile of the drug (LD50 exceeds the therapeutic dose is more than 3000 time).
Established, that the preparation has no mutagenic and carcinogenic, It did not affect reproductive function, It does not have immunotoxic and allergenic properties, does not have any irritant action.
Effects on ability to drive vehicles and management mechanisms
Ingavirin® no sedative action, It does not affect the speed of psychomotor reactions, the drug can be used in people of different professions, incl. require attention and coordination.
Cases of overdose Ingavirin® not disclosed.
Not recommended simultaneous application Ingavirin® with other antiviral drugs.
Occasions interaction Ingavirin® with other drugs is not detected.
The drug is released under the prescription.
The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life - 2 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More